Bradley McGregor
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bradley McGregor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05176288 · Avelumab, Palbociclib and Axitinib in Advanced RCCBradley A. McGregor, MD · withdrawn · Advanced Clear Cell Renal Cell Carcinoma · principal investigator
- Ph2NCT04413123 · Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCBradley A. McGregor, MD · active not recruiting · Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma · principal investigator
- Ph2NCT03097328 · Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell CarcinomaBradley A. McGregor, MD · completed · Renal Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:09 UTC. The ranking covers the 200 most relevant of 48 PubMed records, and a shared surname and initials can bring in a namesake. All 48 on PubMed
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.J Clin Oncol · 2019549 citationsRCR 20.8
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.Lancet Oncol · 2021256 citationsRCR 13.3
- Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer.Psychosom Med · 2000195 citationsRCR 6.0
- 186 citationsRCR 36.4
- Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer.Brain Behav Immun · 2009162 citationsRCR 4.9
- Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer.J Psychosom Res · 2004154 citationsRCR 4.3
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun · 2021152 citationsRCR 7.1
- 148 citationsRCR 11.7
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.N Engl J Med · 2025147 citationsRCR 31.0
- 125 citationsRCR 4.7